{"id":"cjc-1295","name":"CJC-1295","aliases":["CJC-1295 DAC","modified GRF(1-29)","tesamorelin's cousin"],"url":"https://lyoresearch.com/compounds/cjc-1295","summary":"CJC-1295 is a modified growth-hormone-releasing hormone fragment engineered to bind albumin so that it lasts days rather than minutes. Early human trials showed substantial, sustained rises in growth hormone and IGF-1 with weekly dosing. Development was discontinued and no trial has measured whether that translates into any clinical outcome. It is not approved anywhere and is banned in sport.","overall_grade":"C","overall_grade_meaning":"weak human evidence","human_trials":"Early-phase only; programme discontinued","regulatory_status":"Not approved","outcomes":[{"outcome":"Growth hormone / IGF-1 elevation","grade":"B","grade_meaning":"probable, not settled","effect_size":"large","adverse":false,"human_studies":"Phase 1 / early phase 2","evidence":"Weekly dosing produced sustained multi-fold GH increases and IGF-1 elevations over weeks in healthy adults — a large, reproducible effect on the marker.","references":[{"citation":"Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.","where":"J Clin Endocrinol Metab, 2006;91:799–805","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Teichman+CJC-1295+growth+hormone+healthy+adults+2006"}]},{"outcome":"Body composition","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"None","evidence":"No trial has measured muscle or fat change.","references":[]},{"outcome":"Any clinical outcome","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"None","evidence":"The programme was discontinued before efficacy trials in any indication.","references":[]},{"outcome":"Safety in humans","grade":"C","grade_meaning":"weak human evidence","effect_size":"not measurable","adverse":true,"human_studies":"Early-phase only","evidence":"Short early-phase exposure only. Long-term safety of sustained IGF-1 elevation is unstudied.","references":[]}],"regions":[{"region":"European Union","status":"Unapproved medicinal product","note":"No authorisation; sale for human use is an offence for the seller."},{"region":"United States","status":"Not approved","note":"Never approved; development discontinued."},{"region":"Sport (WADA)","status":"Prohibited","note":"GH-releasing factors banned at all times."},{"region":"Australia","status":"Prescription-only or unapproved","note":"Scheduled by the TGA; not available without a prescription."}],"faq":[{"q":"Does CJC-1295 build muscle?","a":"Unknown. It raises growth hormone and IGF-1 substantially — that part is well documented in early trials. Whether that changes muscle or fat has never been measured in a trial."},{"q":"What is the difference between CJC-1295 with and without DAC?","a":"The DAC (drug affinity complex) version binds to albumin and lasts about a week. Without DAC it is essentially modified GRF(1-29), lasting around half an hour. They are sold under the same name."},{"q":"Why was development stopped?","a":"The programme was discontinued after early-phase work, without efficacy trials in any indication."}],"references":[{"cite":"Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.","where":"J Clin Endocrinol Metab, 2006;91:799–805","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Teichman+CJC-1295+growth+hormone+healthy+adults+2006","note":"The early-phase human pharmacology; no outcome endpoints."}],"last_reviewed":"2026-09-02","literature_searched_to":"2026-09-02","changelog":[{"date":"2026-09-02","note":"Initial publication. Hormone effect graded B; all downstream outcomes D."}],"license":"CC BY 4.0 — cite as “LYO Research” with a link.","methodology":"https://lyoresearch.com/methodology"}